QQ客服 官方微博 反馈留言

浏览/检索结果: 共15条，第1-10条 帮助 限定条件 发表日期：2020     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 9 作者:  Dai, Meng-di;  Wang, Yue-liang;  Fan, Jun;  Dai, Yang;  Ji, Yin-chun 收藏  |  浏览/下载：32/0  |  提交时间：2021/05/24 receptor tyrosine kinase  FGFR inhibitor  DW14383  antitumor activity   Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions 期刊论文 THORACIC CANCER, 2020 作者:  Chen, Kaiyan;  Pan, Guoqiang;  Cheng, Guoping;  Zhang, Fanrong;  Xu, Yanjun 收藏  |  浏览/下载：39/0  |  提交时间：2020/12/28 EGFR  HER2  immunotherapy  NSCLC  PD‐  L1   Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients 期刊论文 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 页码: 13 作者:  Liu, Lu;  Wang, Qian;  Xie, Cen;  Xi, Ning;  Guo, Zitao 收藏  |  浏览/下载：55/0  |  提交时间：2020/12/24 drug–  drug interaction  gefitinib  ningetinib  transporters   Non-invasive decision support for NSCLC treatment using PET/CT radiomics 期刊论文 NATURE COMMUNICATIONS, 2020, 卷号: 11, 期号: 1, 页码: 11 作者:  Mu, Wei;  Jiang, Lei;  Zhang, JianYuan;  Shi, Yu;  Gray, Jhanelle E. 收藏  |  浏览/下载：27/0  |  提交时间：2021/01/07 Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins 期刊论文 DRUG METABOLISM AND PHARMACOKINETICS, 2020, 卷号: 35, 期号: 5, 页码: 456-465 作者:  Liu, Xiaoyun;  Feng, Dan;  Zheng, Mingyue;  Cui, Yongmei;  Zhong, Dafang 收藏  |  浏览/下载：13/0  |  提交时间：2020/12/21 Covalent tyrosine kinase inhibitors  Covalent binding  Human serum albumin  Molecular docking  Quantitative calculations  Linear modeling  Species difference   Repurposing of Kinase Inhibitors for Treatment of COVID-19 期刊论文 PHARMACEUTICAL RESEARCH, 2020, 卷号: 37 作者:  Weisberg, Ellen;  Parent, Alexander;  Yang, Priscilla L.;  Sattler, Martin;  Liu, Qingsong 收藏  |  浏览/下载：33/0  |  提交时间：2020/10/26 Coronavirus  SARS-CoV-2  SARS-CoV  MERS-CoV  kinase inhibitors  pharmacokinetics  antiviral therapy  COVID-19   Progress on treatment of MET signaling pathway in non-small cell lung cancer 期刊论文 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020 作者:  Yu, Xiaoqing;  Yu, Sizhe;  Fan, Yun 收藏  |  浏览/下载：24/0  |  提交时间：2020/11/26 MET  Dysregulation  Overexpression  Amplification  Non-small cell lung cancer   Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer 期刊论文 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10 作者:  Lin, Chen;  Shi, Xun;  Zhao, Jun;  He, Qiong;  Fan, Yun 收藏  |  浏览/下载：21/0  |  提交时间：2020/10/26 tumor mutation burden (TMB)  clinical benefit  epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)  chemotherapy  non-small cell lung cancer (NSCLC)   Endosulfan promotes cell migration via PTP4A3-mediated signaling pathways in HUVECs 期刊论文 ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2020, 卷号: 192, 页码: 1-9 作者:  Li, Heng;  Liu, Shiqi;  Hu, Yumeng;  Zhao, Bin;  Sun, Yeqing 收藏  |  浏览/下载：22/0  |  提交时间：2021/09/14 Endosulfan  Cell migration  PTP4A3  Signaling pathway  Endothelial cells   PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy 期刊论文 LUNG CANCER, 2020, 卷号: 142 作者:  Chen, Kaiyan;  Cheng, Guoping;  Zhang, Fanrong;  Zhu, Guanxia;  Xu, Yanjun 收藏  |  浏览/下载：24/0  |  提交时间：2020/11/26 Uncommon EGFR  Non-small cell lung cancer  PD-L1  T cell  Immunotherapy